ÌìÃÀ´«Ã½

ISSN: 2161-0460

Journal of Alzheimers Disease & Parkinsonism
ÌìÃÀ´«Ã½ Access

Our Group organises 3000+ Global Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ ÌìÃÀ´«Ã½ Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

ÌìÃÀ´«Ã½ Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Citations : 4334

Indexed In
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • ÌìÃÀ´«Ã½ J Gate
  • Genamics JournalSeek
  • Academic Keys
  • JournalTOCs
  • China National Knowledge Infrastructure (CNKI)
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • EBSCO A-Z
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • ICMJE
Share This Page

BLOCKING NEUROINFLAMMATION DUE TO COMPLEMENT ACTIVATION BY AMYLOID WITH VACCINIA VIRUS COMPLEMENT CONTROL PROTEIN (VCP), A BETTER ALTERNATIVE TO ADUHELM IN ALZHEIMER�S DISEASE (AD) DUE TO APOE4 PREDISPOSITION

International Conference on Alzheimer and Dementia

Girish J. Kotwal

Kotwal Bioconsulting, USA

ScientificTracks Abstracts: J Alzheimers Dis Parkinsonism

Abstract
Statement of the Problem: Alzheimer�s disease (AD) is primarily a progressive neurodegenerative disease accompanied with memory loss that is primarily due to aging although recently AD is considered to be due to genetic predisposition resulting from the presence of ApoE4 allele. AD is caused by abnormal accumulation of beta amyloid and tau proteins in and around neurons in the brain, affecting synaptic junctions. Both beta amyloid and tau activate complement pathways which then results in neuro inflammation. AD related dementia affects 30+ million people globally and the annual cost of care is estimated at half a trillion. Methodology & Theoretical Orientation: DNA was isolated from saliva of 2 individuals. The sequence of ApoE allele was determined. VCP was purified from overexpression in the yeast system. It was delivered to the brain by 2 routes and found to be effective in transgenic mice in achieving memory protection.. A human trial with a select cohort of about 40 subjects (20 male and 20 female) with homozygous ApoE4 allele above age 55 would be selected. 20 of the subjects will receive VCP and 20 will receive placebo. Various quantitative cognitive and memory parameters will be followed and the benefit of VCP in memory retention will be assessed. Conclusion & Significance: In light of the limitations of the FDA approved treatment Aduhelm for Mild Cognitive impairment, new treatments such as VCP which can be delivered across the blood brain barrier without invasive procedure need to be included in human trials to prevent AD symptoms by early intervention in persons with ApoE4 allele.
Biography

Girish J. Kotwal, Ph.D. has been working on the Alzheimer’s Disease (AD) related neuroinflammation for over 2 decades. He along with his doctoral student James Daly were the first to demonstrate a cause and effect relation between abeta fibrils that contribute to amyloid plaques and neurodefeneration resulting in memory loss and symptoms of AD. He was the first to propose that complement mediated inflammation can be blocked by vaccinia virus complement control protein (VCP). Recently his group has shown that VCP can have improved outcomes in AD mice by delivering without any invasive procedure to the brain, Novel therapeutics like VCP could be a much better and safer alternative to monoclonal antibodies which could have adverse effects by activating the complement pathway thereby increasing neuroinflammation.

International Conferences 2025-26
 
Meet Inspiring Speakers and Experts at our 3000+ Global

Conferences by Country

Medical & Clinical Conferences

Conferences By Subject

Top